Trilaciclib to Protect Bone Marrow in Limited-Stage Small Cell Lung Cancer
Compares trilaciclib with placebo in adults with limited-stage small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Key facts
- Where
- Ostrava, CzechiaSee the 2 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with limited-stage small cell lung cancer. It tests whether trilaciclib protects the blood cells compared with a placebo.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Confirmed limited-stage small cell lung cancer, with disease that can be measured and evaluated
- Earlier treatment
- Must have fully recovered from any earlier surgery to treat the tumour
Main reasons for not taking part
- Extensive-stage small cell lung cancer
- Active cardiovascular disease
- Known allergy to trilaciclib, etoposide, carboplatin, cisplatin or anything in them
- Pregnant or nursing women
Read by machine on 9 November 2026.
Where in Czechia
- Fakultni nemocnice OstravaOstrava, CzechiaNot yet recruiting
- Nemocnice AGEL Ostrava - Vitkovice a.s.Ostrava, CzechiaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Pharmacosmos A/S
- Trial code
- NCT07473128EU 2025-525026-35-00
- Record updated
- 2 October 2026
- Original description
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:Read full original descriptionShow less
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:
Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer?
Participants will be randomised to receive either trilaciclib or placebo.
Inclusion: Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer; Complete recovery from prior anti-tumor surgical procedures; Measurable and evaluable disease through tumor assessment; Willingness to participate and sign informed consent form.
Exclusion: Extensive Stage Small Cell Lung Cancer; Active cardiovascular disease; Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations; Pregnant or nursing women.